Literature DB >> 16534687

Recommendations for improved use of the murine TNBS-induced colitis model in evaluating anti-inflammatory properties of lactic acid bacteria: technical and microbiological aspects.

Benoit Foligné1, Sophie Nutten, Lothar Steidler, Véronique Dennin, Denise Goudercourt, Annick Mercenier, Bruno Pot.   

Abstract

Probiotic bacteria have been shown to exert promising beneficial effects in different types of intestinal disorders, including chronic inflammation. In this context, animal models of inflammatory bowel disease are useful in studying the possible prophylactic role of candidate probiotic strains. This study aimed at evaluating the critical technological and microbiological parameters as well as the robustness of the murine trinitrobenzene sulfonic acid (TNBS)-induced model of colitis, after intragastric administration of lactic acid bacteria (LAB) preparations. A standardized methodology was applied to assess the protective effect achieved by various bacterial concentrations and culture conditions of the reference strain Lactobacillus plantarum NCIMB 8826. Not only was protection found to vary in function in different levels of colitis, but also repeated experiments showed a clear bacterial dose-dependent attenuation of colitis. The physiological stage of bacteria was shown to impact as well, with substantial, mild, or reduced improvement of inflammatory scores for exponentially growing, stationary-phase, or killed bacteria, respectively. A recombinant strain, secreting murine interleukin-10 (IL-10) and previously reported to successfully treat colitis in two different models of murine colitis (dextran sulfate sodium [DSS] and IL-10-deficient mice), was used to validate the final experimental conditions. In conclusion, we identified and optimized some of the key parameters that need to be controlled in order to ensure reliable comparison of results generated over a long period of time or independent experiments. The recommendations for an improved model presented here will prove to be helpful for reproducible, independent comparison of the anti-inflammatory potential of wild-type or recombinant candidate probiotic strains, whether administered as pure cultures or as blends.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16534687     DOI: 10.1007/s10620-006-3143-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  49 in total

1.  Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.

Authors:  P Gionchetti; F Rizzello; A Venturi; P Brigidi; D Matteuzzi; G Bazzocchi; G Poggioli; M Miglioli; M Campieri
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

Review 2.  Probiotics and immune regulation of inflammatory bowel diseases.

Authors:  Yingzi Cong; Astrid Konrad; Nuzhat Iqbal; Charles O Elson
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2003-06

Review 3.  In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings.

Authors:  C Dunne; L O'Mahony; L Murphy; G Thornton; D Morrissey; S O'Halloran; M Feeney; S Flynn; G Fitzgerald; C Daly; B Kiely; G C O'Sullivan; F Shanahan; J K Collins
Journal:  Am J Clin Nutr       Date:  2001-02       Impact factor: 7.045

4.  Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis.

Authors:  J O Lindsay; C J Ciesielski; T Scheinin; F M Brennan; H J Hodgson
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

5.  Colonic bacteria and bacterial translocation in experimental colitis.

Authors:  K R Gardiner; P J Erwin; N H Anderson; J G Barr; M I Halliday; B J Rowlands
Journal:  Br J Surg       Date:  1993-04       Impact factor: 6.939

Review 6.  Probiotics and inflammatory bowel disease: from fads and fantasy to facts and future.

Authors:  Fergus Shanahan
Journal:  Br J Nutr       Date:  2002-09       Impact factor: 3.718

7.  Contrasting activity of cytosin-guanosin dinucleotide oligonucleotides in mice with experimental colitis.

Authors:  F Obermeier; N Dunger; U G Strauch; N Grunwald; H Herfarth; J Schölmerich; W Falk
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

8.  Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance.

Authors:  J McCarthy; L O'Mahony; L O'Callaghan; B Sheil; E E Vaughan; N Fitzsimons; J Fitzgibbon; G C O'Sullivan; B Kiely; J K Collins; F Shanahan
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

Review 9.  Probiotics and the management of inflammatory bowel disease.

Authors:  Richard N Fedorak; Karen L Madsen
Journal:  Inflamm Bowel Dis       Date:  2004-05       Impact factor: 5.325

10.  Nonlymphocyte-derived tumor necrosis factor is required for induction of colitis in recombination activating gene (RAG)2(-/-) mice upon transfer of CD4(+)CD45RB(hi) T cells.

Authors:  N Corazza; S Eichenberger; H P Eugster; C Mueller
Journal:  J Exp Med       Date:  1999-11-15       Impact factor: 14.307

View more
  37 in total

1.  Probiotics in IBD: mucosal and systemic routes of administration may promote similar effects.

Authors:  B Foligné; C Grangette; B Pot
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

2.  Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria.

Authors:  Benoit Foligne; Sophie Nutten; Corinne Grangette; Véronique Dennin; Denise Goudercourt; Sabine Poiret; Joelle Dewulf; Dominique Brassart; Annick Mercenier; Bruno Pot
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

3.  Induction of murine TNBS colitis is strictly controlled by a modified method using continuous inhalation anesthesia with sevoflurane.

Authors:  Tomohiro Terai; Satoshi Osawa; Shinya Tani; Shinji Oishi; Yoshifumi Arai; Takanori Yamada; Mitsushige Sugimoto; Takahisa Furuta; Shigeru Kanaoka; Hiroaki Miyajima; Ken Sugimoto
Journal:  Dig Dis Sci       Date:  2014-01-23       Impact factor: 3.199

4.  Bifidobacterium infantis attenuates colitis by regulating T cell subset responses.

Authors:  Li Zuo; Kai-Tao Yuan; Li Yu; Qing-Hong Meng; Peter Chee-Keung Chung; Ding-Hua Yang
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

5.  Probiotic yeasts: anti-inflammatory potential of various non-pathogenic strains in experimental colitis in mice.

Authors:  Benoît Foligné; Joëlle Dewulf; Pascal Vandekerckove; Georges Pignède; Bruno Pot
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

6.  Proinflammatory and anti-inflammatory cytokines present in the acute phase of experimental colitis treated with Saccharomyces boulardii.

Authors:  Nathália Nahas Grijó; Ricardo Carneiro Borra; Vera Lucia Sdepanian
Journal:  Dig Dis Sci       Date:  2009-12-09       Impact factor: 3.199

7.  Synbiotic Matchmaking in Lactobacillus plantarum: Substrate Screening and Gene-Trait Matching To Characterize Strain-Specific Carbohydrate Utilization.

Authors:  Jori Fuhren; Christiane Rösch; Maud Ten Napel; Henk A Schols; Michiel Kleerebezem
Journal:  Appl Environ Microbiol       Date:  2020-09-01       Impact factor: 4.792

8.  Changes in intestinal Toll-like receptors and cytokines precede histological injury in a rat model of necrotizing enterocolitis.

Authors:  Yuying Liu; Limin Zhu; Nicole Y Fatheree; Xiaoqin Liu; Susan E Pacheco; Nina Tatevian; Jon Marc Rhoads
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-07-16       Impact factor: 4.052

9.  M1 is a major subtype of muscarinic acetylcholine receptors on mouse colonic epithelial cells.

Authors:  Md Rafiqul Islam Khan; Abu Syed Md Anisuzzaman; Shingo Semba; Yanju Ma; Junsuke Uwada; Hisayoshi Hayashi; Yuichi Suzuki; Tomoko Takano; Hiroki Ikeuchi; Motoi Uchino; Atsuo Maemoto; Fumitaka Ushikubi; Ikunobu Muramatsu; Takanobu Taniguchi
Journal:  J Gastroenterol       Date:  2012-12-15       Impact factor: 7.527

10.  Rotavirus-like particles: a novel nanocarrier for the gut.

Authors:  Naima G Cortes-Perez; Catherine Sapin; Loïc Jaffrelo; Sabine Daou; Jean Pierre Grill; Philippe Langella; Philippe Seksik; Laurent Beaugerie; Serge Chwetzoff; Germain Trugnan
Journal:  J Biomed Biotechnol       Date:  2010-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.